Detalhe da pesquisa
1.
Top advances of the year: Perioperative therapy for lung cancer.
Cancer
; 2024 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38717993
2.
Risk model-based management for second primary lung cancer among lung cancer survivors through a validated risk prediction model.
Cancer
; 130(5): 770-780, 2024 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37877788
3.
Implementation and evaluation of an elective quality improvement curriculum for preclinical students: a prospective controlled study.
BMC Med Educ
; 23(1): 66, 2023 Jan 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-36703204
4.
Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine.
Curr Treat Options Oncol
; 19(8): 43, 2018 06 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-29951788
5.
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study.
J Thorac Oncol
; 2024 Jan 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38278303
6.
Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study.
JTO Clin Res Rep
; 4(3): 100459, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36879929
7.
Second Primary Lung Cancer Among Lung Cancer Survivors Who Never Smoked.
JAMA Netw Open
; 6(11): e2343278, 2023 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37966839
8.
Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations.
Clin Cancer Res
; 29(11): 2123-2130, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36913537
9.
Risk Model-Based Lung Cancer Screening and Racial and Ethnic Disparities in the US.
JAMA Oncol
; 9(12): 1640-1648, 2023 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37883107
10.
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
Cancer Discov
; 13(7): 1556-1571, 2023 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37068173
11.
Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer.
Cancer Treat Res Commun
; 30: 100497, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-34920242
12.
EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy.
Clin Lung Cancer
; 23(2): e148-e153, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34391686
13.
Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer.
Cancer Treat Res Commun
; 33: 100659, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36427429
14.
The Survival Impact of Second Primary Lung Cancer in Patients With Lung Cancer.
J Natl Cancer Inst
; 114(4): 618-625, 2022 04 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34893871
15.
Racial and Ethnic Disparities in Lung Cancer Screening by the 2021 USPSTF Guidelines Versus Risk-Based Criteria: The Multiethnic Cohort Study.
JNCI Cancer Spectr
; 6(3)2022 05 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35642317
16.
High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience.
JTO Clin Res Rep
; 3(6): 100328, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35637759
17.
Development and Validation of a Risk Prediction Model for Second Primary Lung Cancer.
J Natl Cancer Inst
; 114(1): 87-96, 2022 01 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34255071
18.
Metabolomic profiling for second primary lung cancer: A pilot case-control study.
Lung Cancer
; 155: 61-67, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33743383
19.
Widespread myofascial dysfunction and sensitisation in women with endometriosis-associated chronic pelvic pain: A cross-sectional study.
Eur J Pain
; 25(4): 831-840, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33326662
20.
Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC.
J Thorac Oncol
; 16(5): 868-872, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33539970